302 related articles for article (PubMed ID: 24119382)
21. Tolterodine extended-release for overactive bladder.
Chung DE; Te AE
Expert Opin Pharmacother; 2009 Sep; 10(13):2181-94. PubMed ID: 19663610
[TBL] [Abstract][Full Text] [Related]
22. Solifenacin for overactive bladder: a systematic review and meta-analysis.
Luo D; Liu L; Han P; Wei Q; Shen H
Int Urogynecol J; 2012 Aug; 23(8):983-91. PubMed ID: 22310924
[TBL] [Abstract][Full Text] [Related]
23. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
[TBL] [Abstract][Full Text] [Related]
24. Solifenacin in the treatment of overactive bladder syndrome in Italian patients: pharmacoeconomic evaluation.
Pradelli L; Iannazzo S
J Med Econ; 2009 Mar; 12(1):25-35. PubMed ID: 19450062
[TBL] [Abstract][Full Text] [Related]
25. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
Jonas U; Rackley RR
Eur Urol; 2006 Jan; 49(1):187-8; author reply 188-90. PubMed ID: 16310930
[No Abstract] [Full Text] [Related]
26. A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.
Peeker R; Samsioe G; Kowalski J; Andersson AS; Bergqvist A
Scand J Urol Nephrol; 2010 Apr; 44(3):138-46. PubMed ID: 20367449
[TBL] [Abstract][Full Text] [Related]
27. Use of health care resources and associated costs in non-institutionalized vulnerable elders with overactive bladder treated with antimuscarinic agents in the usual medical practice.
Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Aguado-Jodar A; Ruíz-Torrejón A
Actas Urol Esp; 2014 Oct; 38(8):530-7. PubMed ID: 24630426
[TBL] [Abstract][Full Text] [Related]
28. Adherence to fesoterodine in women with overactive bladder in routine clinical practice.
Simó M; Porta O; Pubill J; Castillo MT; Mora I; Huguet E; Ortega JA; Martínez E
Actas Urol Esp; 2015 May; 39(4):222-8. PubMed ID: 25442908
[TBL] [Abstract][Full Text] [Related]
29. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
[TBL] [Abstract][Full Text] [Related]
30. Fesoterodine for the treatment of overactive bladder.
Tzefos M; Dolder C; Olin JL
Ann Pharmacother; 2009 Dec; 43(12):1992-2000. PubMed ID: 19920160
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.
Hart WM; Abrams P; Munro V; Retsa P; Nazir J
J Med Econ; 2013 Oct; 16(10):1246-54. PubMed ID: 23885660
[TBL] [Abstract][Full Text] [Related]
32. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
Chapple C
Urologe A; 2007 Apr; 46(4):422, 424-6; author reply 426, 428. PubMed ID: 17384923
[No Abstract] [Full Text] [Related]
33. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
[TBL] [Abstract][Full Text] [Related]
34. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT).
Siami P; Seidman LS; Lama D
Clin Ther; 2002 Apr; 24(4):616-28. PubMed ID: 12017406
[TBL] [Abstract][Full Text] [Related]
35. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Warner JL
BJU Int; 2010 Aug; 106(4):586. PubMed ID: 20653664
[No Abstract] [Full Text] [Related]
36. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial.
Chapple CR; Martinez-Garcia R; Selvaggi L; Toozs-Hobson P; Warnack W; Drogendijk T; Wright DM; Bolodeoku J;
Eur Urol; 2005 Sep; 48(3):464-70. PubMed ID: 15990220
[TBL] [Abstract][Full Text] [Related]
37. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
Goepel M
Urologe A; 2006 Jul; 45(7):847-51. PubMed ID: 16816976
[No Abstract] [Full Text] [Related]
38. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of fesoterodine in women with overactive bladder.
Sand PK; Morrow JD; Bavendam T; Creanga DL; Nitti VW
Int Urogynecol J Pelvic Floor Dysfunct; 2009 Jul; 20(7):827-35. PubMed ID: 19495545
[TBL] [Abstract][Full Text] [Related]
40. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
